Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

Mostrar otras versiones (1)

Octreotide may extend survival in hepatocellular carcinoma (HCC). Forty-one per cent of HCCs have high-affinity somatostatin receptors. We aimed to determine the feasibility, safety, and activity of long-acting octreotide in advanced HCC; to identify the best method for assessing somatostatin recept...

Descripción completa

Detalles Bibliográficos
Autor principal: Cebon, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360532/
https://www.ncbi.nlm.nih.gov/pubmed/16953241
http://dx.doi.org/10.1038/sj.bjc.6603325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360532/
https://www.ncbi.nlm.nih.gov/pubmed/16953241
http://dx.doi.org/10.1038/sj.bjc.6603325

Ejemplares similares